<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01317641</url>
  </required_header>
  <id_info>
    <org_study_id>3104001</org_study_id>
    <nct_id>NCT01317641</nct_id>
  </id_info>
  <brief_title>Safety and Pharmacokinetics Study of ODM-201 in Castrate Resistant Prostate Cancer</brief_title>
  <official_title>Safety and Pharmacokinetics of ODM-201 in Patients With Castrate Resistant Prostate Cancer: Open, Non-randomised, Uncontrolled, Multicentre, Multiple Dose Escalation Study With a Randomised Phase II Expansion Component</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Orion Corporation, Orion Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Endo Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Orion Corporation, Orion Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of ODM-201
      in patients with castrate resistant prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase 1: Number of Participants Who Experienced Dose Limiting Toxicity (DLT)</measure>
    <time_frame>Up to 28 days for each cohort</time_frame>
    <description>A DLT was any Grade 3 or more toxicity (by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE version 4.03]) excluding less than Grade 4 neutropenia or thrombocytopenia, hematological toxicity lasting less than 7 days, and nausea, vomiting, diarrhea controlled with antiemetic and/or anti-diarrheal treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase 1: Number of Dose Limiting Toxicities Used to Determine the Maximum Tolerated Dose</measure>
    <time_frame>Up to 28 days for each cohort</time_frame>
    <description>The MTD is defined as dose level at which 2 or more out of 6 participants experience a dose limiting toxicity (DLT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Chemotherapy-naïve and CYP17i-naïve Group</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants who were naïve to both chemotherapy and CYP17 inhibitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-chemotherapy and CYP17i-naïve Group</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants previously treated with chemotherapy but not CYP17 inhibitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-CYP17i Group</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants previously treated with CYP17 inhibitor</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Participants With RECIST Response in Soft Tissue in Chemotherapy-naïve and CYP17i-naïve Group</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Participants With RECIST Response in Soft Tissue in Post-chemotherapy and CYP17i-naive Group</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Participants With RECIST Responses in Soft Tissue in Post-CYP17i Group</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Participants With Stable Bone Disease in Chemotherapy-naïve and CYP17i-naïve Group</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Participants With Stable Bone Disease in Post-chemotherapy and CYP17i-naïve Group</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1 and 2: Participants With Stable Bone Disease in Post-CYP17i Group</measure>
    <time_frame>3 months</time_frame>
    <description>Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of ODM-201 at Steady-state</measure>
    <time_frame>Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose</time_frame>
    <description>AUC(0-8h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Maximum Plasma Concentration (Cmax) of ODM-201 at Steady-state</measure>
    <time_frame>Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of ODM-201 at Day 1</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of Major Metabolite ORM-15341 at Steady-state</measure>
    <time_frame>Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose</time_frame>
    <description>AUC(0-8h)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Maximum Plasma Concentration (Cmax) of Major Metabolite ORM-15341 at Steady-state</measure>
    <time_frame>Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of Major Metabolite ORM-15341 at Day 1</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">136</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>ODM-201 Phase I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ODM-201 Phase II Dose 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ODM-201 Phase II Dose 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ODM-201 Phase II Dose 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ODM-201</intervention_name>
    <description>ODM-201 administered orally daily</description>
    <arm_group_label>ODM-201 Phase I</arm_group_label>
    <arm_group_label>ODM-201 Phase II Dose 1</arm_group_label>
    <arm_group_label>ODM-201 Phase II Dose 2</arm_group_label>
    <arm_group_label>ODM-201 Phase II Dose 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Histologically confirmed adenocarcinoma of prostate

          -  Ongoing androgen deprivation therapy with a LHRH analogue or antagonist or bilateral
             orchiectomy

          -  Progressive metastatic disease

          -  Adequate bone marrow, hepatic, and renal function

        Exclusion Criteria:

          -  Known metastases in the brain

          -  History of other malignancy within the previous 5 years

          -  Known gastrointestinal disease or procedure that affects the absorption

          -  Not able to swallow the study drug
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Fizazi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Urology Center of Colorado</name>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <zip>80211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern CT Hematology and Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Urology Health Team PLLC</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chesapeake Urology Research Associates</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21327</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delaware Valley urology, LLC</name>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <zip>08043</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooklyn Urology Research Group</name>
      <address>
        <city>Brooklyn</city>
        <state>New York</state>
        <zip>11215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Urologic Research Center</name>
      <address>
        <city>Myrtle Beach</city>
        <state>South Carolina</state>
        <zip>29572</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinika onkologie a radioterapie LFUK a FN</name>
      <address>
        <city>Hradec Králové</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni Nemonicnice Olomouc</name>
      <address>
        <city>Olomouc</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oddeleni Radiacni a Klinicke Onkologie Nemocnice Znojmo</name>
      <address>
        <city>Znojmo</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East-Tallinn Central Hospital</name>
      <address>
        <city>Talinn</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Helsinki University Central Hospital</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kuopio University Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oulu University Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Louis Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Birmingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Velindre Cancer Centre</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Churchill Hospital</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70240-2/fulltext</url>
    <description>Lancet Oncology publication containing study results</description>
  </link>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24974051</url>
    <description>PubMed link to the Lancet Oncology publication containing study results</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 7, 2011</study_first_submitted>
  <study_first_submitted_qc>March 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2011</study_first_posted>
  <results_first_submitted>March 23, 2016</results_first_submitted>
  <results_first_submitted_qc>February 9, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 29, 2017</results_first_posted>
  <last_update_submitted>February 9, 2017</last_update_submitted>
  <last_update_submitted_qc>February 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at 23 hospitals in Europe and in the USA from Apr 5, 2011 to Mar 12, 2013</recruitment_details>
      <pre_assignment_details>136 participants participated in the study, including 24 enrolled in Phase 1 and 112 in Phase 2 randomly assigned to 200 mg, 400 mg or 1400 mg daily doses and stratified by previous chemotherapy and treatment with CYP17 inhibitor. Two participants assigned to treatment did not start ODM-201, and were therefore excluded from analyses populations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase 1: ODM-201 200 mg/Day</title>
          <description>Dose escalation</description>
        </group>
        <group group_id="P2">
          <title>Phase 1: ODM-201 400 mg/Day</title>
          <description>Dose escalation</description>
        </group>
        <group group_id="P3">
          <title>Phase 1: ODM-201 600 mg/Day</title>
          <description>Dose escalation</description>
        </group>
        <group group_id="P4">
          <title>Phase 1: ODM-201 1000 mg/Day</title>
          <description>Dose escalation</description>
        </group>
        <group group_id="P5">
          <title>Phase 1: ODM-201 1400 mg/Day</title>
          <description>Dose escalation</description>
        </group>
        <group group_id="P6">
          <title>Phase 1: ODM-201 1800 mg/Day</title>
          <description>Dose escalation</description>
        </group>
        <group group_id="P7">
          <title>Phase 2: ODM-201 200mg/Day</title>
          <description>Chemotherapy-naïve and CYP17 inhibitor-naïve, Post-chemotherapy and CYP17 inhibitor-naïve, Post-CYP17 inhibitor</description>
        </group>
        <group group_id="P8">
          <title>Phase 2: ODM-201 400mg/Day</title>
          <description>Chemotherapy-naïve and CYP17 inhibitor-naïve, Post-chemotherapy and CYP17 inhibitor-naïve, Post-CYP17 inhibitor</description>
        </group>
        <group group_id="P9">
          <title>Phase 2: ODM-201 1400mg/Day</title>
          <description>Chemotherapy-naïve and CYP17 inhibitor-naïve, Post-chemotherapy and CYP17 inhibitor-naïve, Post-CYP17 inhibitor</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="38"/>
                <participants group_id="P8" count="38"/>
                <participants group_id="P9" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="35"/>
                <participants group_id="P8" count="33"/>
                <participants group_id="P9" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="5"/>
                <participants group_id="P9" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety</population>
      <group_list>
        <group group_id="B1">
          <title>Phase 1, 200mg/Day ODM-201</title>
          <description>Dose escalation. Participants received twice daily of oral ODM-201 continuously.</description>
        </group>
        <group group_id="B2">
          <title>Phase 1, 400mg/Day ODM-201</title>
          <description>Dose escalation. Participants received twice daily of oral ODM-201 continuously.</description>
        </group>
        <group group_id="B3">
          <title>Phase 1, 600mg/Day ODM-201</title>
          <description>Dose escalation. Participants received twice daily of oral ODM-201 continuously.</description>
        </group>
        <group group_id="B4">
          <title>Phase 1, 1000mg/Day ODM-201</title>
          <description>Dose escalation. Participants received twice daily of oral ODM-201 continuously.</description>
        </group>
        <group group_id="B5">
          <title>Phase 1, 1400mg/Day ODM-201</title>
          <description>Dose escalation. Participants received twice daily of oral ODM-201 continuously.</description>
        </group>
        <group group_id="B6">
          <title>Phase 1, 1800mg/Day ODM-201</title>
          <description>Dose escalation. Participants received twice daily of oral ODM-201 continuously.</description>
        </group>
        <group group_id="B7">
          <title>Phase 2 (200mg/Day ODM-201)</title>
          <description>Dose expansion. Participants received twice daily of 200 mg of oral ODM-201 continuously</description>
        </group>
        <group group_id="B8">
          <title>Phase 2 (400mg/Day ODM-201)</title>
          <description>Dose expansion. Participants received twice daily of 200 mg of oral ODM-201 continuously.</description>
        </group>
        <group group_id="B9">
          <title>Phase 2 (1400mg/Day ODM-201)</title>
          <description>Dose expansion. Participants received twice daily of 200 mg of oral ODM-201 continuously.</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="4"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="38"/>
            <count group_id="B8" value="37"/>
            <count group_id="B9" value="35"/>
            <count group_id="B10" value="134"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73" spread="1.4"/>
                    <measurement group_id="B2" value="71.9" spread="8.5"/>
                    <measurement group_id="B3" value="65.3" spread="3.5"/>
                    <measurement group_id="B4" value="65.8" spread="11.2"/>
                    <measurement group_id="B5" value="67.7" spread="5.5"/>
                    <measurement group_id="B6" value="67.7" spread="3.2"/>
                    <measurement group_id="B7" value="68.3" spread="7.0"/>
                    <measurement group_id="B8" value="69.1" spread="7.4"/>
                    <measurement group_id="B9" value="71.3" spread="8.0"/>
                    <measurement group_id="B10" value="69.4" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="38"/>
                    <measurement group_id="B8" value="37"/>
                    <measurement group_id="B9" value="35"/>
                    <measurement group_id="B10" value="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase 1: Number of Participants Who Experienced Dose Limiting Toxicity (DLT)</title>
        <description>A DLT was any Grade 3 or more toxicity (by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE version 4.03]) excluding less than Grade 4 neutropenia or thrombocytopenia, hematological toxicity lasting less than 7 days, and nausea, vomiting, diarrhea controlled with antiemetic and/or anti-diarrheal treatment.</description>
        <time_frame>Up to 28 days for each cohort</time_frame>
        <population>Safety population included all participants in Phase 1 who received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: ODM-201 200 mg/Day</title>
            <description>Participants received twice daily of oral ODM-201 continuously.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: ODM-201 400 mg/Day</title>
            <description>Participants received twice daily of oral ODM-201 continuously.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: ODM-201 600 mg/Day</title>
            <description>Participants received twice daily of oral ODM-201 continuously.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1: ODM-201 1000 mg/Day</title>
            <description>Participants received twice daily of oral ODM-201 continuously.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1: ODM-201 1400 mg/Day</title>
            <description>Participants received twice daily of oral ODM-201 continuously.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: ODM-201 1800 mg/Day</title>
            <description>Participants received twice daily of oral ODM-201 continuously.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Number of Participants Who Experienced Dose Limiting Toxicity (DLT)</title>
          <description>A DLT was any Grade 3 or more toxicity (by National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE version 4.03]) excluding less than Grade 4 neutropenia or thrombocytopenia, hematological toxicity lasting less than 7 days, and nausea, vomiting, diarrhea controlled with antiemetic and/or anti-diarrheal treatment.</description>
          <population>Safety population included all participants in Phase 1 who received any study drug.</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase 1: Number of Dose Limiting Toxicities Used to Determine the Maximum Tolerated Dose</title>
        <description>The MTD is defined as dose level at which 2 or more out of 6 participants experience a dose limiting toxicity (DLT)</description>
        <time_frame>Up to 28 days for each cohort</time_frame>
        <population>Safety population included all participants in Phase 1 who received any study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1: ODM-201 200 mg/Day</title>
            <description>Participants received twice daily of oral ODM-201 continuously.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1: ODM-201 400 mg/Day</title>
            <description>Participants received twice daily of oral ODM-201 continuously.</description>
          </group>
          <group group_id="O3">
            <title>Phase 1: ODM-201 600 mg/Day</title>
            <description>Participants received twice daily of oral ODM-201 continuously.</description>
          </group>
          <group group_id="O4">
            <title>Phase 1: ODM-201 1000 mg/Day</title>
            <description>Participants received twice daily of oral ODM-201 continuously.</description>
          </group>
          <group group_id="O5">
            <title>Phase 1: ODM-201 1400 mg/Day</title>
            <description>Participants received twice daily of oral ODM-201 continuously.</description>
          </group>
          <group group_id="O6">
            <title>Phase 1: ODM-201 1800 mg/Day</title>
            <description>Participants received twice daily of oral ODM-201 continuously.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Number of Dose Limiting Toxicities Used to Determine the Maximum Tolerated Dose</title>
          <description>The MTD is defined as dose level at which 2 or more out of 6 participants experience a dose limiting toxicity (DLT)</description>
          <population>Safety population included all participants in Phase 1 who received any study drug.</population>
          <units>DLTs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Chemotherapy-naïve and CYP17i-naïve Group</title>
        <description>Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants who were naïve to both chemotherapy and CYP17 inhibitor</description>
        <time_frame>3 months</time_frame>
        <population>Evaluable chemotherapy-naïve and CYP17i-naïve patients</population>
        <group_list>
          <group group_id="O1">
            <title>200mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O2">
            <title>400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O3">
            <title>600mg/Day ODM-201</title>
            <description>phase 1</description>
          </group>
          <group group_id="O4">
            <title>1000mg/Day ODM-201</title>
            <description>phase 1</description>
          </group>
          <group group_id="O5">
            <title>1400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O6">
            <title>1800mg/Day ODM-201</title>
            <description>phase 1</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Chemotherapy-naïve and CYP17i-naïve Group</title>
          <description>Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants who were naïve to both chemotherapy and CYP17 inhibitor</description>
          <population>Evaluable chemotherapy-naïve and CYP17i-naïve patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="7"/>
                <count group_id="O6" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-chemotherapy and CYP17i-naïve Group</title>
        <description>Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants previously treated with chemotherapy but not CYP17 inhibitor</description>
        <time_frame>3 months</time_frame>
        <population>Evaluable post-chemotherapy and CYP17i-naïve patients</population>
        <group_list>
          <group group_id="O1">
            <title>200mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O2">
            <title>400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O3">
            <title>600mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O4">
            <title>1000mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O5">
            <title>1400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O6">
            <title>1800mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-chemotherapy and CYP17i-naïve Group</title>
          <description>Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants previously treated with chemotherapy but not CYP17 inhibitor</description>
          <population>Evaluable post-chemotherapy and CYP17i-naïve patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="11"/>
                <count group_id="O6" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-CYP17i Group</title>
        <description>Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants previously treated with CYP17 inhibitor</description>
        <time_frame>3 months</time_frame>
        <population>Evaluable post-CYP17 inhibitor patients</population>
        <group_list>
          <group group_id="O1">
            <title>200mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O2">
            <title>400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O3">
            <title>1000mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O4">
            <title>1400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: Participants With Decline of at Least 50% in Prostate-specific Antigen (PSA) in Post-CYP17i Group</title>
          <description>Number of participants with greater than or equal to 50% decrease in serum PSA from baseline at 12 weeks in group of participants previously treated with CYP17 inhibitor</description>
          <population>Evaluable post-CYP17 inhibitor patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: Participants With RECIST Response in Soft Tissue in Chemotherapy-naïve and CYP17i-naïve Group</title>
        <description>Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.</description>
        <time_frame>3 months</time_frame>
        <population>Evaluable Chemotherapy-naïve and CYP17i-naïve patients</population>
        <group_list>
          <group group_id="O1">
            <title>200mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O2">
            <title>400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O3">
            <title>600mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O4">
            <title>1400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O5">
            <title>1800mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: Participants With RECIST Response in Soft Tissue in Chemotherapy-naïve and CYP17i-naïve Group</title>
          <description>Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.</description>
          <population>Evaluable Chemotherapy-naïve and CYP17i-naïve patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RECIST response CR+PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RECIST response CR+PR+SD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                    <measurement group_id="O5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: Participants With RECIST Response in Soft Tissue in Post-chemotherapy and CYP17i-naive Group</title>
        <description>Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.</description>
        <time_frame>3 months</time_frame>
        <population>Evaluable Post-chemotherapy and CYP17i-naïve patients</population>
        <group_list>
          <group group_id="O1">
            <title>200mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O2">
            <title>400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O3">
            <title>1000mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O4">
            <title>1400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O5">
            <title>1800mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: Participants With RECIST Response in Soft Tissue in Post-chemotherapy and CYP17i-naive Group</title>
          <description>Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.</description>
          <population>Evaluable Post-chemotherapy and CYP17i-naïve patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RECIST response CR+PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RECIST response CR+PR+SD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: Participants With RECIST Responses in Soft Tissue in Post-CYP17i Group</title>
        <description>Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.</description>
        <time_frame>3 months</time_frame>
        <population>Evaluable Post-CYP17i patients</population>
        <group_list>
          <group group_id="O1">
            <title>200mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O2">
            <title>400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O3">
            <title>1400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: Participants With RECIST Responses in Soft Tissue in Post-CYP17i Group</title>
          <description>Number of participants with overall complete response (CR), partial response (PR) or stable (SD) soft tissue disease according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) in chest, abdomen, and pelvic CT or MRI scans.</description>
          <population>Evaluable Post-CYP17i patients</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>RECIST response CR+PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RECIST response CR+PR+SD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: Participants With Stable Bone Disease in Chemotherapy-naïve and CYP17i-naïve Group</title>
        <description>Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan</description>
        <time_frame>3 months</time_frame>
        <population>Evaluable chemotherapy-naïve and CYP17i-naïve patients with bone metastasis at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>200mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O2">
            <title>400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O3">
            <title>1000mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O4">
            <title>1400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O5">
            <title>1800mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: Participants With Stable Bone Disease in Chemotherapy-naïve and CYP17i-naïve Group</title>
          <description>Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan</description>
          <population>Evaluable chemotherapy-naïve and CYP17i-naïve patients with bone metastasis at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="7"/>
                <count group_id="O5" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: Participants With Stable Bone Disease in Post-chemotherapy and CYP17i-naïve Group</title>
        <description>Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan</description>
        <time_frame>3 months</time_frame>
        <population>Evaluable Post-chemotherapy and CYP17i-naïve patients with bone metastasis at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>200mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O2">
            <title>400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O3">
            <title>600mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O4">
            <title>1000mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O5">
            <title>1400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: Participants With Stable Bone Disease in Post-chemotherapy and CYP17i-naïve Group</title>
          <description>Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan</description>
          <population>Evaluable Post-chemotherapy and CYP17i-naïve patients with bone metastasis at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1 and 2: Participants With Stable Bone Disease in Post-CYP17i Group</title>
        <description>Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan</description>
        <time_frame>3 months</time_frame>
        <population>Evaluable post-CYP17i patients with bone metastasis at baseline</population>
        <group_list>
          <group group_id="O1">
            <title>200mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O2">
            <title>400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
          <group group_id="O3">
            <title>1000mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O4">
            <title>1400mg/Day ODM-201</title>
            <description>expanded dose level (phase 1 + phase 2)</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1 and 2: Participants With Stable Bone Disease in Post-CYP17i Group</title>
          <description>Number of participants with stable bone disease (no change). Radiographic bone progression was defined by the appearance of two or more new lesions on bone scan</description>
          <population>Evaluable post-CYP17i patients with bone metastasis at baseline</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of ODM-201 at Steady-state</title>
        <description>AUC(0-8h)</description>
        <time_frame>Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose</time_frame>
        <population>PK population (Day 8)</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O2">
            <title>400 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O3">
            <title>600 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O4">
            <title>1000 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O5">
            <title>1400 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O6">
            <title>1800 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of ODM-201 at Steady-state</title>
          <description>AUC(0-8h)</description>
          <population>PK population (Day 8)</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6387.27" spread="742.01"/>
                    <measurement group_id="O2" value="10973.66" spread="5939.78"/>
                    <measurement group_id="O3" value="14205.99" spread="2127.26"/>
                    <measurement group_id="O4" value="14817.39" spread="4190.48"/>
                    <measurement group_id="O5" value="31764.82" spread="8714.06"/>
                    <measurement group_id="O6" value="28884.44" spread="4900.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Maximum Plasma Concentration (Cmax) of ODM-201 at Steady-state</title>
        <time_frame>Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose</time_frame>
        <population>PK population (Day 8)</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O2">
            <title>400 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O3">
            <title>600 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O4">
            <title>1000 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O5">
            <title>1400 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O6">
            <title>1800 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Maximum Plasma Concentration (Cmax) of ODM-201 at Steady-state</title>
          <population>PK population (Day 8)</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1011.67" spread="168.84"/>
                    <measurement group_id="O2" value="1757.57" spread="858.72"/>
                    <measurement group_id="O3" value="2033.00" spread="277.59"/>
                    <measurement group_id="O4" value="2392.33" spread="406.63"/>
                    <measurement group_id="O5" value="4459.00" spread="1163.10"/>
                    <measurement group_id="O6" value="4235.00" spread="617.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of ODM-201 at Day 1</title>
        <time_frame>1 day</time_frame>
        <population>PK population (Day 1)</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O2">
            <title>400 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O3">
            <title>600 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O4">
            <title>1000 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O5">
            <title>1400 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O6">
            <title>1800 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of ODM-201 at Day 1</title>
          <population>PK population (Day 1)</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="1.63"/>
                    <measurement group_id="O2" value="3.00" spread="0.73"/>
                    <measurement group_id="O3" value="3.00" spread="0.92"/>
                    <measurement group_id="O4" value="5.08" spread="1.47"/>
                    <measurement group_id="O5" value="3.00" spread="1.15"/>
                    <measurement group_id="O6" value="5.00" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of Major Metabolite ORM-15341 at Steady-state</title>
        <description>AUC(0-8h)</description>
        <time_frame>Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose</time_frame>
        <population>PK population (Day 8)</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O2">
            <title>400 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O3">
            <title>600 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O4">
            <title>1000 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O5">
            <title>1400 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O6">
            <title>1800 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Area Under the Plasma-Concentration-time Curve (AUCt) of Major Metabolite ORM-15341 at Steady-state</title>
          <description>AUC(0-8h)</description>
          <population>PK population (Day 8)</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11754.23" spread="5161.80"/>
                    <measurement group_id="O2" value="15501.56" spread="2755.85"/>
                    <measurement group_id="O3" value="24902.56" spread="12129.79"/>
                    <measurement group_id="O4" value="29980.83" spread="11658.75"/>
                    <measurement group_id="O5" value="63531.81" spread="15798.30"/>
                    <measurement group_id="O6" value="64435.97" spread="22930.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Maximum Plasma Concentration (Cmax) of Major Metabolite ORM-15341 at Steady-state</title>
        <time_frame>Day 8 predose 0 h and 0.5, 1, 1.5, 2, 4, 6 and 8 h postdose</time_frame>
        <population>PK population (Day 8)</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O2">
            <title>400 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O3">
            <title>600 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O4">
            <title>1000 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O5">
            <title>1400 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O6">
            <title>1800 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Maximum Plasma Concentration (Cmax) of Major Metabolite ORM-15341 at Steady-state</title>
          <population>PK population (Day 8)</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1850.00" spread="654.83"/>
                    <measurement group_id="O2" value="2491.43" spread="328.86"/>
                    <measurement group_id="O3" value="3963.33" spread="1935.21"/>
                    <measurement group_id="O4" value="4643.33" spread="1340.01"/>
                    <measurement group_id="O5" value="9336.67" spread="2054.27"/>
                    <measurement group_id="O6" value="9406.67" spread="3165.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of Major Metabolite ORM-15341 at Day 1</title>
        <time_frame>1 day</time_frame>
        <population>PK population (Day 1)</population>
        <group_list>
          <group group_id="O1">
            <title>200 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O2">
            <title>400 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O3">
            <title>600 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O4">
            <title>1000 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O5">
            <title>1400 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
          <group group_id="O6">
            <title>1800 mg/Day ODM-201</title>
            <description>Phase 1</description>
          </group>
        </group_list>
        <measure>
          <title>Phase 1: Time to Reach the Maximum Observed Concentration (Tmax) of Major Metabolite ORM-15341 at Day 1</title>
          <population>PK population (Day 1)</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="7"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="1.63"/>
                    <measurement group_id="O2" value="1.52" spread="1.33"/>
                    <measurement group_id="O3" value="3.00" spread="0.92"/>
                    <measurement group_id="O4" value="5.04" spread="2.05"/>
                    <measurement group_id="O5" value="3.00" spread="1.15"/>
                    <measurement group_id="O6" value="5.00" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>Phase 1 dose escalation and Phase 2 per dose</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase 1, 200mg/Day ODM-201</title>
          <description>Dose escalation</description>
        </group>
        <group group_id="E2">
          <title>Phase 1, 400mg/Day ODM-201</title>
          <description>Dose escalation</description>
        </group>
        <group group_id="E3">
          <title>Phase 1, 600mg/Day ODM-201</title>
          <description>Dose escalation</description>
        </group>
        <group group_id="E4">
          <title>Phase 1, 1000mg/Day ODM-201</title>
          <description>Dose escalation</description>
        </group>
        <group group_id="E5">
          <title>Phase 1, 1400mg/Day ODM-201</title>
          <description>Dose escalation</description>
        </group>
        <group group_id="E6">
          <title>Phase 1, 1800mg/Day ODM-201</title>
          <description>Dose escalation</description>
        </group>
        <group group_id="E7">
          <title>Phase 2, 200mg/Day ODM-201</title>
          <description>Dose expansion</description>
        </group>
        <group group_id="E8">
          <title>Phase 2, 400mg/Day ODM-201</title>
          <description>Dose expansion</description>
        </group>
        <group group_id="E9">
          <title>Phase 2, 1400mg/Day ODM-201</title>
          <description>Dose expansion</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Muscle injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="33" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="35" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="27" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Motion sickness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Cardiac murmur</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Urine output increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Head of Oncology</name_or_title>
      <organization>Orion Pharma, Development, R&amp;D</organization>
      <phone>+358 10 4261</phone>
      <email>mika.mustonen@orionpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

